Peptide YY (PYY): The Gut's Satiety Signal Explained

Satiety Peptides

30% calorie reduction

When PYY3-36 was infused into obese subjects, they ate 30% fewer calories at a buffet lunch two hours later, matching the response seen in lean subjects.

Batterham et al., New England Journal of Medicine, 2003

Batterham et al., New England Journal of Medicine, 2003

View as image

After a meal, specialized cells in your intestinal lining release a 36-amino acid peptide called PYY into the bloodstream. PYY travels to the brain and activates Y2 receptors in the arcuate nucleus of the hypothalamus, silencing the hunger-promoting neurons (NPY/AgRP) and indirectly activating the satiety-promoting neurons (POMC). The result: you stop feeling hungry and push away from the table. This system works well in lean individuals. In obesity, PYY release is blunted, creating a biological deficit in the "stop eating" signal that compounds the behavioral and environmental drivers of overeating. PYY has been studied as a potential anti-obesity therapy for over two decades. Its interaction with GLP-1 (both are released from the same gut L cells) has become central to understanding why drugs like semaglutide and tirzepatide work as well as they do. For the complete picture of how satiety peptides coordinate meal termination, see CCK (Cholecystokinin): The First Satiety Peptide Discovered.

What PYY Is and Where It Comes From

Peptide YY is a member of the neuropeptide Y (NPY) family, named for the tyrosine (Y) residues at both ends of the molecule. It exists in two forms: PYY1-36 (the full-length peptide) and PYY3-36 (the truncated, biologically active form produced when dipeptidyl peptidase-4, the same enzyme that degrades GLP-1, cleaves the first two amino acids).

PYY is produced primarily by enteroendocrine L cells in the distal small intestine and colon. These same L cells also produce GLP-1 and oxyntomodulin, making them a central hub for post-meal satiety signaling. PYY release is triggered by nutrients reaching the lower gut, with fat being the most potent stimulus, followed by protein and carbohydrates.

Blood levels of PYY rise within 15-30 minutes of eating, peak at 60-90 minutes, and remain elevated for several hours. This timing corresponds to the transition from active eating to the post-meal satiety period. The speed of PYY release relative to when nutrients reach the distal gut suggests both neural (vagal) and direct nutrient-sensing mechanisms are involved.^[7]

How PYY Suppresses Appetite

PYY3-36 crosses the blood-brain barrier and binds to Y2 receptors on NPY/AgRP neurons in the arcuate nucleus of the hypothalamus. Y2 receptors are presynaptic inhibitory autoreceptors: when activated, they suppress the release of NPY and AgRP, two of the most potent appetite-stimulating peptides in the brain.

By silencing these hunger neurons, PYY indirectly disinhibits neighboring POMC/CART neurons, which release alpha-MSH and other anorexigenic signals. The net effect is a coordinated shift from hunger to satiety.^[6]

Challis and colleagues (2003) demonstrated that peripheral PYY3-36 injection in mice reduced food intake and altered hypothalamic neuropeptide expression, confirming the gut-brain signaling pathway in vivo.^[1] Halatchev and colleagues (2004) showed that PYY3-36 inhibited food intake through a mechanism partially independent of melanocortin-4 receptors, suggesting multiple downstream pathways mediate its anorexigenic effects.^[1]

PYY also slows gastric emptying, reduces gallbladder motility, and decreases pancreatic exocrine secretion, collectively referred to as the "ileal brake." This slows nutrient transit through the gut, prolonging nutrient absorption and extending the satiety signal.

PYY Deficiency in Obesity

One of the most consistent findings in PYY research is that obese individuals have lower circulating PYY levels than lean controls, both at fasting and after meals.

Le Roux and colleagues (2006) measured postprandial PYY release in obese and lean subjects and found that the PYY response to a meal was attenuated in obesity. The degree of PYY deficiency correlated with body fat mass and measures of adiposity.^[3]

Karra and colleagues (2009) reviewed the evidence and proposed that reduced PYY secretion in obesity creates a self-perpetuating cycle: lower PYY leads to reduced satiety, increased food intake, greater caloric storage, and further suppression of PYY release.^[6]

The landmark 2003 NEJM study by Batterham and colleagues showed that when PYY3-36 was infused intravenously into obese subjects, they ate 30% fewer calories at a subsequent buffet. Lean subjects showed a 31% reduction. This proved that the PYY signaling machinery remains intact in obesity; the problem is insufficient endogenous PYY production, not receptor insensitivity.

Renshaw and Bloom (2005) identified PYY as a potential therapeutic target for obesity based on these findings, noting that exogenous PYY administration could bypass the secretion deficit.^[2]

PYY and Bariatric Surgery

Roux-en-Y gastric bypass (RYGB) is the most effective long-term treatment for severe obesity, producing sustained weight loss of 25-35% of total body weight. A major driver of this success is the dramatic increase in post-meal gut peptide secretion, particularly PYY and GLP-1.

Le Roux and colleagues (2007) showed that RYGB patients had elevated postprandial PYY and GLP-1 levels compared to both their pre-surgical baseline and non-surgical controls. When PYY and GLP-1 signaling was pharmacologically blocked in RYGB patients, appetite returned and food intake increased, demonstrating that these peptides are not just bystanders but active mediators of post-surgical appetite suppression.^[4]

Gil and colleagues (2025) extended these findings by showing that RYGB improves both insulin response and secretion of GLP-1 and PYY in response to post-meal exercise, suggesting synergy between physical activity and surgical gut remodeling.^[10]

The bariatric surgery data provides the strongest evidence that PYY is a causal mediator of satiety in humans, not merely a biomarker. For the full picture of how GLP-1 and PYY interact with other gut hormones after surgery, see How GLP-1, PYY, and CCK Work Together to Stop You from Eating.

PYY, Exercise, and Diet

Exercise acutely suppresses appetite, and PYY appears to be one mediator of this effect.

Broom and colleagues (2009) measured circulating PYY levels in healthy males after resistance and aerobic exercise. Both exercise types increased PYY levels and suppressed subjective hunger ratings. The PYY elevation was transient, lasting 1-2 hours post-exercise.^[5]

Jones and colleagues (2009) found that long-term exercise training in overweight adolescents improved plasma PYY levels, suggesting that sustained physical activity can partially reverse the PYY deficit seen in obesity.^[5]

Alyar and colleagues (2024) measured ghrelin, GLP-1, and PYY changes after diet and exercise interventions in obese individuals, finding that combined approaches produced the most favorable gut peptide profiles.^[9]

Dietary composition also affects PYY release. High-protein meals generate the strongest PYY responses, followed by fat and then carbohydrate. This is one mechanism underlying protein's well-established effect on satiety. Short-chain fatty acids from fiber fermentation in the colon also stimulate L cell PYY secretion, linking dietary fiber intake to appetite regulation.

PYY Beyond Appetite: IBS and Taste

PYY's role extends beyond simple appetite suppression.

El-Salhy (2020) reviewed PYY's involvement in irritable bowel syndrome (IBS), noting that altered PYY levels in IBS patients correlate with gut motility disturbances, visceral hypersensitivity, and abnormal secretory function. PYY's role in the ileal brake makes it a candidate mediator of the transit abnormalities seen in both diarrhea-predominant and constipation-predominant IBS.^[8]

Iyer and colleagues (2025) demonstrated that oral application of PYY and exendin-4 (a GLP-1 agonist) influenced taste-related behavior and taste perception in mice. PYY altered preferences for specific taste qualities, suggesting that gut peptides do not just regulate how much we eat but what we want to eat.^[11] This finding has implications for understanding the food preference changes reported by patients on GLP-1 drugs.

PYY as a Therapeutic Target

Despite two decades of research establishing PYY's role in satiety, no PYY-based drug has been approved.

The barriers are familiar for peptide therapeutics: PYY3-36 has a short half-life (minutes), must be injected, and high doses cause nausea. Early clinical studies found that the therapeutic window between appetite suppression and nausea was narrow.

Steinert and colleagues (2017) comprehensively reviewed the secretory controls and physiological roles of the four major appetite-regulating gut peptides (ghrelin, CCK, GLP-1, and PYY) and noted that combination approaches targeting multiple peptides simultaneously are more likely to succeed than single-peptide therapies.^[7]

This insight underlies the success of GLP-1-based drugs. Semaglutide and tirzepatide primarily target GLP-1 (and GIP) receptors, but bariatric surgery data shows that PYY contributes substantially to the appetite suppression achieved by surgery. Future combination therapies that include PYY agonism alongside GLP-1 activation could potentially match surgical outcomes without surgical intervention. The relationship between PYY and other appetite hormones connects to Oxyntomodulin: The Natural Dual Agonist That Suppresses Appetite and Pancreatic Polypeptide: The Underappreciated Appetite Regulator.

The PYY-GLP-1 Axis

PYY and GLP-1 are co-secreted from the same L cells, share the same nutrient stimuli, and are both degraded by DPP-4. Their effects on appetite are additive: blocking either one partially restores appetite in post-bariatric patients, but blocking both has a larger effect.

The co-secretion means that interventions that boost GLP-1 (high-protein diets, fiber, DPP-4 inhibitors) also boost PYY. The drugs classified as "GLP-1 agonists" do not directly activate PYY receptors, but the physiological PYY system contributes to the overall appetite suppression seen with dietary and surgical interventions.

Long-acting PYY analogs and Y2 receptor agonists are in preclinical development. The challenge is achieving sustained receptor activation without the nausea that accompanies acute PYY surges, mirroring the dose-titration journey that GLP-1 drugs went through. For how PYY deficiency connects to broader metabolic dysfunction, see Leptin Resistance: Why the "I'm Full" Signal Stops Working in Obesity.

The Bottom Line

PYY is a 36-amino acid gut peptide released by intestinal L cells after meals that suppresses appetite through Y2 receptors in the hypothalamic arcuate nucleus. Obese individuals produce less PYY, contributing to impaired satiety, but retain full sensitivity to exogenous PYY (30% calorie reduction when infused). Roux-en-Y gastric bypass dramatically increases PYY secretion, and blocking PYY in surgical patients restores appetite, confirming its causal role. Exercise and high-protein diets increase PYY levels. No PYY-based drug is approved due to short half-life and nausea at therapeutic doses, but the PYY-GLP-1 co-secretion axis is central to understanding why gut-targeted obesity interventions work.

Frequently Asked Questions

What is peptide YY and what does it do?

Peptide YY (PYY) is a 36-amino acid hormone released by L cells in the intestine after eating. Its active form, PYY3-36, travels through the bloodstream to the brain, where it activates Y2 receptors in the hypothalamus to suppress hunger-promoting neurons. PYY signals that a meal is sufficient and reduces further food intake. It also slows gastric emptying and intestinal transit through the "ileal brake" mechanism.

Do obese people have less PYY?

Yes. Multiple studies show that obese individuals have lower fasting and postprandial PYY levels than lean controls, and the deficit correlates with body fat mass.^[3][6] When PYY3-36 is infused into obese subjects, they reduce food intake by 30%, showing that the problem is insufficient PYY production rather than resistance to the peptide's effects.

How does PYY relate to GLP-1 drugs like semaglutide?

PYY and GLP-1 are co-produced by the same intestinal L cells and both suppress appetite. Semaglutide directly activates GLP-1 receptors but does not activate PYY receptors. However, bariatric surgery (which increases both PYY and GLP-1) produces greater appetite suppression than GLP-1 drugs alone, suggesting PYY contributes additional satiety signaling. Future combination drugs targeting both pathways could potentially approach surgical outcomes.^[7]

Does exercise increase PYY levels?

Both aerobic and resistance exercise acutely increase circulating PYY levels and suppress hunger in the hours after a workout.^[5] Long-term exercise training in overweight adolescents improved baseline PYY levels, suggesting sustained physical activity partially reverses the PYY deficit associated with obesity. Combined diet and exercise interventions produce the most favorable gut peptide profiles.^[9]

Why is there no PYY drug for weight loss?

PYY3-36 has a half-life of only minutes, requires injection, and causes nausea at doses needed for appetite suppression. The therapeutic window between effective appetite reduction and intolerable nausea is narrow. Long-acting PYY analogs and Y2 receptor agonists are in preclinical development but face the same dose-optimization challenges that GLP-1 drugs overcame through slow dose titration.

What foods increase PYY release?

High-protein meals trigger the strongest PYY release from gut L cells, followed by fat and then carbohydrate. Dietary fiber increases PYY through short-chain fatty acid production by colonic bacteria, which directly stimulates L cells. Consuming adequate protein and fiber at meals is the most reliable dietary strategy for enhancing natural PYY secretion and post-meal satiety.